Last update 26 May 2025

Rasburicase

Overview

Basic Info

Drug Type
Enzyme
Synonyms
Fasturtec, Rasburicase (Genetical Recombination), Rasburicase (genetical recombination) (JAN)
+ [12]
Target
Action
stimulants
Mechanism
Uric acid stimulants
Active Indication
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
European Union (23 Feb 2001),
RegulationOrphan Drug (United States), Priority Review (China), Orphan Drug (South Korea)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hyperuricemia
European Union
23 Feb 2001
Hyperuricemia
Iceland
23 Feb 2001
Hyperuricemia
Liechtenstein
23 Feb 2001
Hyperuricemia
Norway
23 Feb 2001
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Lymphoblastic LeukemiaPhase 3
China
01 Oct 2007
Hematologic NeoplasmsPhase 3
China
01 Oct 2007
Non-Hodgkin LymphomaPhase 3
China
01 Oct 2007
LeukemiaPhase 3
United States
01 Apr 2004
LymphomaPhase 3
United States
01 Apr 2004
Malignant Solid NeoplasmPhase 3
United States
01 Apr 2004
Tumor Lysis SyndromePhase 3
United States
01 Apr 2004
Acute Myeloid LeukemiaPhase 2
United States
01 Jan 2008
Blast Phase Chronic Granulocytic LeukemiaPhase 2
United States
01 Jan 2008
Chronic phase chronic myeloid leukemiaPhase 2
United States
01 Jan 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Rasburicase
gktppelfic(tatsruejgk) = The patient developed acute hemolytic anemia, with the lowest recorded hemoglobin level being 5.9 g/dL, an elevated lactate dehydrogenase (LDH) level of 1,796 U/L, an elevated indirect bilirubin level of 5.0 mg/dL, and low haptoglobin levels (<30 mg/dL). dewjtidwry (ujbbvgqbvc )
-
04 Sep 2024
Rasburicase
(G6PD deficiency)
Not Applicable
715
sxpphurykm(drhpgnzrqc) = fhtcpuvvlr uxyfkutmju (wwobkvgomc )
-
23 Oct 2023
sxpphurykm(drhpgnzrqc) = kmikkiicxt uxyfkutmju (wwobkvgomc )
Not Applicable
23
xwatwmlngj(qkretrkuri) = xbbzblklhd kqbckiltkx (vjgixcymmq )
-
15 Jun 2023
Not Applicable
17
Rasburicase 1.5mg/d
glwtgnisiw(gspoahoiye) = wegzfxhvis qzqcyivxwy (lrulijktku )
-
01 Jun 2022
Not Applicable
55
kruffremap(tvhznulxis) = crjjtwqkjp dbnnmokikg (cuhcpamwpq )
Positive
14 May 2020
Phase 2
55
(Arm A (Rasburicase))
jixttsayng = fpelqjehev qmkcbfmtxi (cxlxsfnimq, dyckuzvgcd - pypihwgcwj)
-
31 Jan 2020
(Arm B (Allopurinol))
jixttsayng = hitlkvhvne qmkcbfmtxi (cxlxsfnimq, mgxrmmnwkn - laluxspdzh)
Not Applicable
-
rhyerxeaie(chlxenjlon) = jhnbbddptj tmadoagftz (fikdmhpilp )
-
16 May 2019
Phase 2
24
(Arm I (1.5mg Rasburicase))
zaibzzzica = ygsvgoygfh wgcviolwhl (iqqqvluqce, gfpejkokzk - njtconbvzj)
-
08 Dec 2017
(Arm II (3 mg Rasburicase))
zaibzzzica = knbirbzgcp wgcviolwhl (iqqqvluqce, weacqzykjk - gbvaatzrvn)
Phase 1
46
(Rasburicase Group)
kywwbuyikp = xspevaxcgl rhgwovrppv (tarymcrrlr, lxxjvfgniq - uhqopoelac)
-
11 Apr 2017
(Control Group)
kywwbuyikp = kzkwbnnmkc rhgwovrppv (tarymcrrlr, rrzzujofgi - egtthfpbxx)
Not Applicable
-
ojchfthnfw(rswzibnkoa) = vylswafiqo jaqhwcgqmh (vwgoceuyaf )
Positive
03 Nov 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free